Literature DB >> 20955919

Declining antimicrobial susceptibility of Streptococcus pneumoniae in the United States: report from the SENTRY Antimicrobial Surveillance Program (1998-2009).

Ronald N Jones, Helio S Sader, Gary J Moet, David J Farrell.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20955919     DOI： 10.1016/j.diagmicrobio.2010.08.024

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN： 0732-8893            Impact factor:   2.803


× No keyword cloud information.
  23 in total

1.  LEADER Program results for 2009: an activity and spectrum analysis of linezolid using 6,414 clinical isolates from 56 medical centers in the United States.

Authors:  David J Farrell; Rodrigo E Mendes; James E Ross; Helio S Sader; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

Review 2.  Management of community-acquired pneumonia in older adults.

Authors:  Antonella F Simonetti; Diego Viasus; Carolina Garcia-Vidal; Jordi Carratalà
Journal:  Ther Adv Infect Dis       Date:  2014-02

3.  Serotype emergence and genotype distribution among macrolide-resistant invasive Streptococcus pneumoniae isolates in the postconjugate vaccine (PCV-7) era.

Authors:  Zhenying Liu; Irving Nachamkin; Paul H Edelstein; Ebbing Lautenbach; Joshua P Metlay
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

4.  Multiple mutations and increased RNA expression in tetracycline-resistant Streptococcus pneumoniae as determined by genome-wide DNA and mRNA sequencing.

Authors:  Andréanne Lupien; Hélène Gingras; Michel G Bergeron; Philippe Leprohon; Marc Ouellette
Journal:  J Antimicrob Chemother       Date:  2015-04-09       Impact factor: 5.790

Review 5.  Risk Factors for Drug-Resistant Cap in Immunocompetent Patients.

Authors:  Francisco Arancibia; Mauricio Ruiz
Journal:  Curr Infect Dis Rep       Date:  2017-03       Impact factor: 3.725

6.  Fluoroquinolones in community-acquired pneumonia: guide to selection and appropriate use.

Authors:  Christopher R Frei; Matthew J Labreche; Russell T Attridge
Journal:  Drugs       Date:  2011-04-16       Impact factor: 9.546

7.  Ceftobiprole activity against over 60,000 clinical bacterial pathogens isolated in Europe, Turkey, and Israel from 2005 to 2010.

Authors:  David J Farrell; Robert K Flamm; Helio S Sader; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2014-04-28       Impact factor: 5.191

8.  Molecular characteristics of penicillin-binding protein 2b, 2x and 1a sequences in Streptococcus pneumoniae isolates causing invasive diseases among children in Northeast China.

Authors:  X Zhou; J Liu; Z Zhang; Y Liu; Y Wang; Y Liu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-03-14       Impact factor: 3.267

9.  Antimicrobial activity of ceftaroline tested against drug-resistant subsets of Streptococcus pneumoniae from U.S. medical centers.

Authors:  Robert K Flamm; Helio S Sader; David J Farrell; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191

10.  Dalbavancin Activity When Tested against Streptococcus pneumoniae Isolated in Medical Centers on Six Continents (2011 to 2014).

Authors:  Ronald N Jones; Jason E Schuchert; Rodrigo E Mendes
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.